Brett E Johnson
Overview
Explore the profile of Brett E Johnson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
5236
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schupp P, Shelton S, Brody D, Eliscu R, Johnson B, Mazor T, et al.
Cancers (Basel)
. 2024 Jul;
16(13).
PMID: 39001492
Tumors may contain billions of cells, including distinct malignant clones and nonmalignant cell types. Clarifying the evolutionary histories, prevalence, and defining molecular features of these cells is essential for improving...
2.
Johnson B, Borges E, Gaspari R, Galletta G, Lai J
Am J Psychiatry
. 2024 Jan;
181(1):81-82.
PMID: 38161298
No abstract available.
3.
Schupp P, Shelton S, Brody D, Eliscu R, Johnson B, Mazor T, et al.
bioRxiv
. 2023 Aug;
PMID: 37645893
Tumors may contain billions of cells including distinct malignant clones and nonmalignant cell types. Clarifying the evolutionary histories, prevalence, and defining molecular features of these cells is essential for improving...
4.
Johnson B, Creason A, Stommel J, Keck J, Parmar S, Betts C, et al.
Cell Rep Med
. 2022 Mar;
3(2):100525.
PMID: 35243422
Mechanisms of therapeutic resistance and vulnerability evolve in metastatic cancers as tumor cells and extrinsic microenvironmental influences change during treatment. To support the development of methods for identifying these mechanisms...
5.
Li A, Keck J, Parmar S, Patterson J, Labrie M, Creason A, et al.
NPJ Precis Oncol
. 2021 Mar;
5(1):28.
PMID: 33772089
Molecular heterogeneity in metastatic breast cancer presents multiple clinical challenges in accurately characterizing and treating the disease. Current diagnostic approaches offer limited ability to assess heterogeneity that exists among multiple...
6.
Burlingame E, McDonnell M, Schau G, Thibault G, Lanciault C, Morgan T, et al.
Sci Rep
. 2020 Oct;
10(1):17507.
PMID: 33060677
Spatially-resolved molecular profiling by immunostaining tissue sections is a key feature in cancer diagnosis, subtyping, and treatment, where it complements routine histopathological evaluation by clarifying tumor phenotypes. In this work,...
7.
Mazor T, Pankov A, Johnson B, Hong C, Hamilton E, Bell R, et al.
Cancer Cell
. 2015 Sep;
28(3):307-317.
PMID: 26373278
The evolutionary history of tumor cell populations can be reconstructed from patterns of genetic alterations. In contrast to stable genetic events, epigenetic states are reversible and sensitive to the microenvironment,...
8.
van Thuijl H, Mazor T, Johnson B, Fouse S, Aihara K, Hong C, et al.
Acta Neuropathol
. 2015 Mar;
129(4):597-607.
PMID: 25724300
Temozolomide (TMZ) increases the overall survival of patients with glioblastoma (GBM), but its role in the clinical management of diffuse low-grade gliomas (LGG) is still being defined. DNA hypermethylation of...
9.
Nagarajan R, Zhang B, Bell R, Johnson B, Olshen A, Sundaram V, et al.
Genome Res
. 2014 Apr;
24(5):761-74.
PMID: 24709822
Aberrant DNA hypomethylation may play an important role in the growth rate of glioblastoma (GBM), but the functional impact on transcription remains poorly understood. We assayed the GBM methylome with...
10.
Johnson B, Mazor T, Hong C, Barnes M, Aihara K, McLean C, et al.
Science
. 2013 Dec;
343(6167):189-193.
PMID: 24336570
Tumor recurrence is a leading cause of cancer mortality. Therapies for recurrent disease may fail, at least in part, because the genomic alterations driving the growth of recurrences are distinct...